AACE2021-A-1017: To Compare Incidence of Autonomic Neuropathy and Microalbuminuria as Risk Marker for Cardiovascular Events in Patients with Diabetes Mellitus

2021 ◽  
Vol 27 (12) ◽  
pp. S17
Author(s):  
Vinod Joseph Thomas Choondal ◽  
Kashif Bin Naeem ◽  
Najiba Abdulrazzaq
Keyword(s):  
Diabetes Mellitus ◽  
Autonomic Neuropathy ◽  
Cardiovascular Events ◽  
Risk Marker ◽  
Patients With Diabetes

scholarly journals Angiotensin receptor blockers in nephroprotection at patients with diabetes mellitus: focus on losartan

2009 ◽  
Vol 6 (3) ◽  
pp. 33-37
Author(s):  
Ol'ga Konstantinovna Vikulova ◽  
Marina Vladimirovna Shestakova
Keyword(s):  
Diabetes Mellitus ◽  
Cardiovascular Events ◽  
Antihypertensive Effect ◽  
Angiotensin Receptor Blockers ◽  
Adverse Event Rate ◽  
Atherosclerosis Progression ◽  
Target Organs ◽  
Patients With Diabetes ◽  
Receptor Blockers ◽  
Losartan Treatment

Many large studies have provided strong evidence that there is an association of elevated BP with a risk for cardiovascular events (CVE), such as stroke, myocardial infarction and heart failure. But none of the studies has indicated that a drug is more effective than another one in reducing the risk for CVE and death. The article summarizes the available data on ramipril in hypertensive patients of high cardiovascular risk. The results of studies demonstrate strong and long-lasting antihypertensive effect of losartan. Moreover, losartan treatment decreases cardiovascular events rate, damage of target organs, atherosclerosis progression and new cases of diabetes mellitus. Losartan shows both high efficacy and low adverse event rate.

Sign in / Sign up

Export Citation Format

Share Document